MarketPulse

CNS tumor

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

REGENXBIO Securities Fraud Lawsuit: Investors Sought for $RGNX Class Action

Schall Law Firm seeks investors in $RGNX securities fraud class action over allegedly misleading statements about RGX-111 clinical trial data.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

REGENXBIO Faces Securities Fraud Class Action Over RGX-111 Disclosure Failures

REGENXBIO faces securities fraud lawsuit over alleged misrepresentations about RGX-111's safety and efficacy. A CNS tumor discovery contradicted prior investor statements, causing shareholder losses.
RGNXsecurities fraudclass action lawsuit
BenzingaBenzinga··Business Wire

REGENXBIO Faces Class Action Lawsuit Over RGX-111 Safety Disclosures

REGENXBIO faces securities fraud lawsuit for allegedly making false statements about RGX-111 safety while withholding adverse trial data from investors between February 2022 and January 2026.
RGNXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Gainey Mckenna & Egleston

Securities Lawsuit Filed Against REGENXBIO Over Gene Therapy Trial Disclosures

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.
RGNXsecurities fraudclass action lawsuit